Your search for apixaban returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Post remove
Drugs in the Pipeline remove

Your search for apixaban returned 17 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Eliquis Achieves Primary Outcome in Phase 3 VTE Study

Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 AMPLIFY-EXT trial, which evaluated treatment with Eliquis (apixaban) over a one-year period compared to placebo for the prevention of recurrent venous thromboembolism (VTE) in patients who had already completed 6-12 months of anticoagulation treatment for VTE, including deep vein thrombosis (DVT) or pulmonary embolism (PE).
Drugs in the Pipeline

Phase 3 Trial Update of Eliquis for Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation

Bristol-Myers Squibb and Pfizer announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin (Coumadin; Bristol-Myers Squibb) in the Phase 3 ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation; these were results from a subanalysis from the study.
Drugs in the Pipeline

FDA Issues Complete Response Letter to NDA for Eliquis

Bristol-Myers Squibb and Pfizer announced that the FDA has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Drugs in the Pipeline

Phase 3 Study of Eliquis for Stroke Prevention

Bristol-Myers Squib and Pfizer announced results from their Phase 3 ARISTOTLE study of Eliquis (apixaban tablet) in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke.